China: How to strategise and win in the world's fastest changing healthcare market
In this paper, our experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch a brand effectively in this exciting region.
With a population of 1.4 billion people China has always been an attractive prize to the pharmaceutical industry. However, China has historically been a tough market to crack and few multinational companies have seen a good return on their investment. But in 2019, the 70th anniversary of the communist party’s victory, the outlook has changed completely and now pharma is rushing to leverage the many opportunities that China offers.
The vaccine opportunity in Asia infographic
Asia is the home to 60% of the world’s population and is one of the fastest growing vaccine markets in the world. A rising demand for better healthcare infrastructure and high awareness levels of the benefits of immunisation are the major factors boosting the vaccine market growth. In our latest infographic we explore the vaccine opportunity in Asia, packed full with all of the latest facts and figures from the region.
Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?
China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets
It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics.
Experience conducting research in South East Asia
Our emerging markets team has considerable expertise conducting research in South East Asia, with our Asia headquarters located in Singapore, we can support your market research needs. We have conducted over 150 healthcare market research projects across South East Asia covering a wide variety of research objectives and over 25 therapy areas, for both local and international organisations.
How we helped our client to understand the opportunities across Asia and other emerging markets using interactive outputs
Our client needed to understand why the use of statins in type 2 diabetes patients in South Korea, China, Thailand and other developing countries is low / sub-optimal. Research was required to understand the diabetic patient journey in order to assess the opportunities to expand HCP knowledge on the importance of lipid lowering for type 2 diabetes patients. The client also wanted to explore the drivers and barriers which would influence uptake.